Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 9/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384671 | 0.89 | KIT (0.49) | TRPV1TDP1LIMK2F10 | |
| SCHEMBL2385012 | 0.87 | TRPV1 (0.55) | TRPV1LIMK2KDRF10CACNA1G | |
| SCHEMBL2385749 | 0.84 | P2RY12 (0.47) | TDP1KDRDRD2DRD4DRD3 | |
| SCHEMBL2382762 | 0.82 | TRPV1 (0.55) | TRPV1KDRF10CACNA1GCACNA1H | |
| SCHEMBL2384457 | 0.79 | HRH4 (0.51) | TRPV1LIMK2F10 | |
| SCHEMBL2382825 | 0.78 | TRPV1 (0.51) | TRPV1LIMK2KDRF10CACNA1G | |
| SCHEMBL2383043 | 0.76 | TRPV1 (0.57) | TRPV1LIMK2KDRF10 | |
| SCHEMBL2385139 | 0.76 | TRPV1 (0.57) | TRPV1LIMK2KDRF10 | |
| SCHEMBL2383147 | 0.75 | MEN1 (0.45) | KDRDRD2DRD4DRD3 | |
| SCHEMBL2384143 | 0.74 | TRPV1 (0.52) | TRPV1LIMK2KDRF10CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885TDP1 3142/4885LIMK2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.